Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada
Jean-Eric Tarride1,2, Mahbubul Haq1, Valerie H Taylor3, Arya M Sharma4, Hamid Reza Nakhai-Pour1, Daria O’Reilly1,2, Feng Xie1,2, Lisa Dolovich2,5,6, Ron Goeree1,2
1Programs for Assessment of Technology in Health (PATH) Research Institute, St Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; 3Department of Psychiatry, University of Toronto, Ontario, Canada; 4Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; 5Centre for Evaluation of Medicines, St Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada; 6Department of Family Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada
Background: Obesity is today’s principal neglected public health problem, as a rising proportion of adults will succumb to the medical complications of obesity. However, little is known about the burden of obesity in adults living in Ontario.
Objectives: To present an overview of the human and economic burden associated with BMI categories in Ontario, Canada, in terms of socio-demographics, comorbidities, health-related quality of life (HRQoL) and costs associated with hospitalization, same day procedures and physician visits.
Methods: The records of all Ontarians who participated in the Canadian Community Health Survey (CCHS), cycle 1.1 and provided consent to data linkage were linked to three administrative databases. Socio-demographic variables, medical characteristics, HRQoL, one year hospitalization, day procedure and physician costs were described per BMI category. Regression analyses were conducted to identify predictors of medical characteristics, HRQoL and costs.
Results: More than 50% of adult participants were either overweight or obese in 2000/2001. Obese adults, and to a lesser extent overweight adults, were more likely to report physician-diagnosed comorbid conditions, to use medications, and to have a lower HRQoL. After covariate adjustment, the hospitalization and physician costs were respectively 40% and 22% higher among obese and overweight adults than among normal-weight adults. No statistical cost differences were observed between normal and underweight individuals or between normal and overweight individuals. HRQoL was significantly lower in underweight and obese adults when compared to normal-weight individuals.
Conclusions: Due to the large human and economic burden associated with under- or excess-weight, policies promoting healthy weight should remain a priority for governments and employers.
Keywords: health-related quality of life, costs, body mass index categories, Ontario
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Other article by this author:
Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated influenza vaccine (TIV) for Canadian children and adolescents
Tarride JE, Burke N, Von Keyserlingk C, O'Reilly D, Xie F, Goeree R
Published Date: 4 October 2012
Readers of this article also read:
Human papillomavirus 16 infection predicts poor outcome in patients with esophageal squamous cell carcinoma
Xi R, Zhang X, Chen X, Pan S, Hui B, Zhang L, Fu S, Li X, Zhang X, Gong T, Guo J, Che S
Published Date: 5 March 2015
Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases
Degli Esposti L, Saragoni S, Buda S, Sturani A, Degli Esposti E
Published Date: 14 May 2013
Walzer S, Travers K, Rieder S, Erazo-Fischer E, Matusiewicz D
Published Date: 3 May 2013
Mohsenin A, Mohsenin V, Adelman RA
Published Date: 26 April 2013
Rachmut IH, Samuels N, Melnick SJ, Ramachandran C, Sharabi Y, Pavlovsky A, Maimon Y, Shoham J
Published Date: 24 April 2013
Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges
Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS
Published Date: 15 April 2013
Health expenditure comparison of extended-release metoprolol succinate and immediate-release metoprolol tartarate
Vaidya V, Patel P
Published Date: 7 February 2012
Jalil MA, Moongfangklang N, Innate K, Mitatha S, Ali J, Yupapin PP
Published Date: 19 October 2011
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Noreddin AM, Elkhatib WF, Cunnion KM, Zhanel GG
Published Date: 7 October 2011